This page contains information about prescription medications. According to the Russian regulatory requirements, this information can be available only for medical or pharmaceutical stuff.

Do you confirm that you are a medical of pharmaceutical specialist?

Report an adverse reaction
Main pageOur products


INN: imiglucerase

Indications for use

The drug is a modified form of beta-glucocerebrosidase, obtained recombinantly. Imiglucerase replaces the deficiency of this enzyme, relieves initial pathophysiological changes and prevents the development of secondary pathological manifestations of the disease.

Glurazyme® treatment reduces size of spleen and liver, improves or normalizes blood platelet counts and mineral bone density, reduces bone-marrow infiltration and also weakens pain in the bones.

Glurazyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease

Glurazyme is indicated for use in adult and pediatric patients: for long-term enzyme replacement therapy for patients with a confirmed diagnosis of Gaucher disease type 1 (without neuronopathic manifestations) and type 3 (with chronic neuronopathic manifestations), who have clinically significant manifestations of Gaucher disease, having one or more of the following symptoms:

  • Anemia
  • Thrombocytopenia
  • Bone diseases
  • Hepatomegaly and splenomegaly

GENERIUM is the only company in Russia that carried out the development and production of Imiglucerase biosimilar.

ЛП-005297 от 17.01.2019